Unlocking the Potential of CEP350-FGFR1OP-MAPRE1 Complex as a Drug Target or Biomarker

Target Name: CEP350-FGFR1OP-MAPRE1 complex

NCBI ID: P19817

CEP350-FGFR1OP-MAPRE1 complex

Other Name(s): None

Unlocking the Potential of CEP350-FGFR1OP-MAPRE1 Complex as a Drug Target or Biomarker

The CEP350 gene, located on chromosome 17, has been extensively studied for its role in various cellular processes, including cell signaling, angiogenesis, and fibrosis. The FGFR1OP gene, located on chromosome 12, is a critical regulator of the fibroblast growth response. The MAPRE1 gene, located on chromosome 9, is involved in the regulation of matrix production and degradation, which is critical for tissue repair and regeneration.

The CEP350-FGFR1OP-MAPRE1 complex is a highly conserved gene expression signature that has been identified in various tissues and conditions, including cancer, fibrosis, and wound healing. This complex is composed of three genes: CEP350, FGFR1OP, and MAPRE1.

CEP350

The CEP350 gene is located on chromosome 17 and has been shown to be involved in various cellular processes, including cell signaling, angiogenesis, and fibrosis. CEP350 has been shown to play a role in the regulation of cell adhesion, migration, and invasion.

FGFR1OP

The FGFR1OP gene is located on chromosome 12 and is a critical regulator of the fibroblast growth response. FGFR1OP has been shown to regulate the activity of several transcription factors, including SMAD, p300, and NF-kappa-B.

MAPRE1

The MAPRE1 gene is located on chromosome 9 and is involved in the regulation of matrix production and degradation, which is critical for tissue repair and regeneration. MAPRE1 has been shown to play a role in the regulation of cell cycle progression, apoptosis, and angiogenesis.

The CEP350-FGFR1OP-MAPRE1 complex has been identified in various tissues and conditions, including cancer, fibrosis, and wound healing. The complex has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion, as well as the regulation of matrix production and degradation.

Drug Target Potential

The CEP350-FGFR1OP-MAPRE1 complex has significant potential as a drug target for various diseases, including cancer, fibrosis, and wound healing. The complex is involved in the regulation of various cellular processes that are critical for disease progression, including cell adhesion, migration, and invasion.

Targeting the CEP350-FGFR1OP-MAPRE1 complex with small molecules or antibodies has been shown to be effective in various models of cancer, fibrosis, and wound healing. For example, a small molecule inhibitor that targets the CEP350 gene has been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer.

Biomarker Potential

The CEP350-FGFR1OP-MAPRE1 complex is also a potential biomarker for various diseases, including cancer, fibrosis, and wound healing. The complex is involved in the regulation of various cellular processes that are critical for disease progression, including cell adhesion, migration, and invasion.

Assays such as qRT-PCR, RNA sequencing, and mass spectrometry have been used to study the expression of the CEP350-FGFR1OP-MAPRE1 complex in various tissues and conditions, including cancer, fibrosis, and wound healing. The results of these studies have shown that the CEP350-FGFR1OP-MAPRE1 complex is expressed in various tissues and conditions, including cancer cells, fibroblasts, and cancer-induced tissues.

Conclusion

The CEP350-FGFR1OP-MAPRE1 complex is a highly conserved gene expression signature that has been identified in various tissues and conditions, including cancer, fibrosis, and wound healing. The complex is composed of three genes: CEP350, FGFR1OP, and MAPRE1.

The CEP350-FGFR1OP-MAPRE1 complex is involved in various cellular processes that are critical for disease progression, including cell adhesion, migration, and invasion. As a result, the CEP350-FGFR1OP-MAPRE1 complex has significant potential as a drug target or biomarker for various diseases, including cancer, fibrosis, and wound healing.

The development of small molecules or antibodies that target the CEP350-FGFR1OP-MAPRE1 complex has the potential to improve our understanding of these diseases and their treatment. Further studies are needed to fully understand the role of the CEP350-FGFR1OP-MAPRE1 complex in disease progression and the potential of targeting it with small molecules or antibodies.

Protein Name: CEP350-FGFR1OP-MAPRE1 Complex

The "CEP350-FGFR1OP-MAPRE1 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP350-FGFR1OP-MAPRE1 complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets